Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries

Carolyn T. Thorpe, Nicole Fowler, Katherine Harrigan, Xinhua Zhao, Yihuang Kang, Joseph T. Hanlon, Walid F. Gellad, Loren J. Schleiden, Joshua M. Thorpe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries. Design: Retrospective cohort study. Setting: Secondary analysis of 2009–10 enrollment, claims, and Part D prescription data for a 10% national sample of U.S. Medicare fee-for-service beneficiaries. Participants: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). Measurements: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection. Results: Overall, 3,481 (4.1%) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9% later added the other class, and 2% switched classes. Of initiators, 23% discontinued within 1 month, and 62% discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95% confidence interval (CI) = 1.10–1.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95% CI = 1.34–1.82) and black (aHR = 1.25, 95% CI = 1.08–1.44) beneficiaries discontinued at a faster rate than white beneficiaries. Conclusion: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed.

Original languageEnglish (US)
Pages (from-to)1806-1814
Number of pages9
JournalJournal of the American Geriatrics Society
Volume64
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Medicare
Hispanic Americans
Confidence Intervals
Pharmaceutical Preparations
Memantine
Fee-for-Service Plans
Cholinesterase Inhibitors
Prescriptions
Dementia
Alzheimer Disease
Cohort Studies
Retrospective Studies
Odds Ratio
Research
hydroquinone

Keywords

  • antidementia medications
  • dementia
  • health disparities
  • Medicare
  • medication discontinuation

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries. / Thorpe, Carolyn T.; Fowler, Nicole; Harrigan, Katherine; Zhao, Xinhua; Kang, Yihuang; Hanlon, Joseph T.; Gellad, Walid F.; Schleiden, Loren J.; Thorpe, Joshua M.

In: Journal of the American Geriatrics Society, Vol. 64, No. 9, 01.09.2016, p. 1806-1814.

Research output: Contribution to journalArticle

Thorpe, CT, Fowler, N, Harrigan, K, Zhao, X, Kang, Y, Hanlon, JT, Gellad, WF, Schleiden, LJ & Thorpe, JM 2016, 'Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries', Journal of the American Geriatrics Society, vol. 64, no. 9, pp. 1806-1814. https://doi.org/10.1111/jgs.14403
Thorpe, Carolyn T. ; Fowler, Nicole ; Harrigan, Katherine ; Zhao, Xinhua ; Kang, Yihuang ; Hanlon, Joseph T. ; Gellad, Walid F. ; Schleiden, Loren J. ; Thorpe, Joshua M. / Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries. In: Journal of the American Geriatrics Society. 2016 ; Vol. 64, No. 9. pp. 1806-1814.
@article{b4b2eb1162254d688bc785eb8427ac30,
title = "Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries",
abstract = "Objectives: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries. Design: Retrospective cohort study. Setting: Secondary analysis of 2009–10 enrollment, claims, and Part D prescription data for a 10{\%} national sample of U.S. Medicare fee-for-service beneficiaries. Participants: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). Measurements: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection. Results: Overall, 3,481 (4.1{\%}) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9{\%} later added the other class, and 2{\%} switched classes. Of initiators, 23{\%} discontinued within 1 month, and 62{\%} discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95{\%} confidence interval (CI) = 1.10–1.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95{\%} CI = 1.34–1.82) and black (aHR = 1.25, 95{\%} CI = 1.08–1.44) beneficiaries discontinued at a faster rate than white beneficiaries. Conclusion: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed.",
keywords = "antidementia medications, dementia, health disparities, Medicare, medication discontinuation",
author = "Thorpe, {Carolyn T.} and Nicole Fowler and Katherine Harrigan and Xinhua Zhao and Yihuang Kang and Hanlon, {Joseph T.} and Gellad, {Walid F.} and Schleiden, {Loren J.} and Thorpe, {Joshua M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/jgs.14403",
language = "English (US)",
volume = "64",
pages = "1806--1814",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries

AU - Thorpe, Carolyn T.

AU - Fowler, Nicole

AU - Harrigan, Katherine

AU - Zhao, Xinhua

AU - Kang, Yihuang

AU - Hanlon, Joseph T.

AU - Gellad, Walid F.

AU - Schleiden, Loren J.

AU - Thorpe, Joshua M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objectives: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries. Design: Retrospective cohort study. Setting: Secondary analysis of 2009–10 enrollment, claims, and Part D prescription data for a 10% national sample of U.S. Medicare fee-for-service beneficiaries. Participants: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). Measurements: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection. Results: Overall, 3,481 (4.1%) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9% later added the other class, and 2% switched classes. Of initiators, 23% discontinued within 1 month, and 62% discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95% confidence interval (CI) = 1.10–1.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95% CI = 1.34–1.82) and black (aHR = 1.25, 95% CI = 1.08–1.44) beneficiaries discontinued at a faster rate than white beneficiaries. Conclusion: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed.

AB - Objectives: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries. Design: Retrospective cohort study. Setting: Secondary analysis of 2009–10 enrollment, claims, and Part D prescription data for a 10% national sample of U.S. Medicare fee-for-service beneficiaries. Participants: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). Measurements: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection. Results: Overall, 3,481 (4.1%) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9% later added the other class, and 2% switched classes. Of initiators, 23% discontinued within 1 month, and 62% discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95% confidence interval (CI) = 1.10–1.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95% CI = 1.34–1.82) and black (aHR = 1.25, 95% CI = 1.08–1.44) beneficiaries discontinued at a faster rate than white beneficiaries. Conclusion: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed.

KW - antidementia medications

KW - dementia

KW - health disparities

KW - Medicare

KW - medication discontinuation

UR - http://www.scopus.com/inward/record.url?scp=84987810064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987810064&partnerID=8YFLogxK

U2 - 10.1111/jgs.14403

DO - 10.1111/jgs.14403

M3 - Article

C2 - 27549029

AN - SCOPUS:84987810064

VL - 64

SP - 1806

EP - 1814

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 9

ER -